for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Roche Holding Ltd.

ROG.S

Latest Trade

327.95CHF

Change

7.00(+2.18%)

Volume

3,265,838

Today's Range

322.45

 - 

328.75

52 Week Range

253.75

 - 

328.75

As of on the Virt-X ∙ Minimum 15 minute delay

Latest Developments

Illumina And Roche Partner To Broaden Patient Access To Genomic Testing

Jan 13 (Reuters) - Illumina Inc <ILMN.O>::ILLUMINA AND ROCHE PARTNER TO BROADEN PATIENT ACCESS TO GENOMIC TESTING.ILLUMINA INC - FINANCIAL TERMS OF DEAL WERE NOT DISCLOSED.ILLUMINA - UNDER TERMS , ROCHE WILL DEVELOP, MANUFACTURE & COMMERCIALIZE AVENIO IVD TESTS FOR BOTH TISSUE & BLOOD FOR USE ON CO'S NEXTSEQ 550DX SYSTEM.ILLUMINA INC - CO WILL CONTINUE TO SELL NEXTSEQ 550DX SYSTEMS AND CORE SEQUENCING CONSUMABLES.ILLUMINA - ANNOUNCED 15 YEAR, NON-EXCLUSIVE COLLABORATION AGREEMENT WITH ROCHE.ILLUMINA - WILL LEAD DEVELOPMENT AND REGULATORY APPROVAL PROCESS, AND WILL CONTINUE TO MANUFACTURE, SUPPLY AND COMMERCIALIZE TSO 500.

Sarepta Therapeutics Announces Partnership With Roche In Territories Outside The United States

Dec 23 (Reuters) - Sarepta Therapeutics Inc <SRPT.O>::SAREPTA THERAPEUTICS ANNOUNCES PARTNERSHIP WITH ROCHE IN TERRITORIES OUTSIDE THE UNITED STATES FOR ITS INVESTIGATIONAL MICRO-DYSTROPHIN GENE THERAPY FOR DUCHENNE MUSCULAR DYSTROPHY, SRP-9001.SAREPTA THERAPEUTICS - TO RECEIVE UPFRONT PAYMENT OF $1.15 BILLION, COMPRISING $750 MILLION IN CASH AND $400 MILLION IN SAREPTA STOCK, PRICED AT $158.59 PER SHARE.

Arcus Biosciences Announces Two Randomized Clinical Studies To Advance Ab928, A Dual Adenosine Receptor Antagonist, Into Novel Combinations For Colorectal And Pancreatic Cancers

Dec 18 (Reuters) - Arcus Biosciences Inc <RCUS.N>::ARCUS BIOSCIENCES, IN COLLABORATION WITH GENENTECH, ANNOUNCES TWO RANDOMIZED CLINICAL STUDIES TO ADVANCE AB928, A DUAL ADENOSINE RECEPTOR ANTAGONIST, INTO NOVEL COMBINATIONS FOR COLORECTAL AND PANCREATIC CANCERS.ARCUS BIOSCIENCES INC - ADDITIONAL FINANCIAL TERMS OF COLLABORATION WITH GENENTECH WERE NOT DISCLOSED.ARCUS BIOSCIENCES INC - UNDER AGREEMENT, CO, GENENTECH IS SUPPLYING ITS RESPECTIVE ANTI-CANCER AGENT TO SUPPORT TRIAL AND JOINTLY FUNDING STUDIES.

Roche, Spark Therapeutics Announce Completion Of Acquisition

Dec 17 (Reuters) - Roche Holding AG <ROG.S>::ROCHE CONCLUDES ACQUISITION OF SPARK THERAPEUTICS, INC. TO STRENGTHEN PRESENCE IN GENE THERAPY.ROCHE, SPARK THERAPEUTICS ANNOUNCE COMPLETION OF ACQUISITION FOLLOWING RECEIPT OF REGULATORY APPROVAL FROM ALL GOVERNMENT AUTHORITIES REQUIRED BY MERGER AGREEMENT.

Roche, Spark Therapeutics Announce Clearance By Uk Authority

Dec 16 (Reuters) - Roche Holding Ag <ROG.S>::ROCHE AND SPARK THERAPEUTICS, INC. ANNOUNCE UNCONDITIONAL CLEARANCE BY UK COMPETITION AND MARKETS AUTHORITY.THE OFFERING PERIOD OF THE OFFER IS SCHEDULED TO EXPIRE AT 5:00 P.M., NEW YORK CITY TIME, ON MONDAY, DECEMBER 16, 2019, UNLESS IT IS EXTENDED FURTHER.

Roche Publishes New Positive Phase 3 Results For Tecentriq

Dec 13 (Reuters) - Roche Holding AG <ROG.S>::POSITIVE PHASE III STUDY RESULTS FOR TECENTRIQ PLUS COTELLIC AND ZELBORAF IN PEOPLE WITH PREVIOUSLY UNTREATED BRAF V600 MUTATION-POSITIVE ADVANCED MELANOMA.A SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENT IN PFS WAS DEMONSTRATED IN STUDY.

Roche Holding AG Fixed-Dose Combination Administered Under Skin In Just Minutes, Compared To Hours With Intravenous Administration, Significantly Reducing Time Spent Receiving Treatment

Roche Holding AG <ROG.S>::ROCHE’S FIXED-DOSE SUBCUTANEOUS COMBINATION OF PERJETA AND HERCEPTIN COMPARABLE TO INTRAVENOUS FORMULATIONS IN PEOPLE WITH HER2-POSITIVE BREAST CANCER.PHASE III FEDERICA STUDY SHOWED NON-INFERIOR PHARMACOKINETICS AND COMPARABLE EFFICACY AND SAFETY WITH FIXED-DOSE COMBINATION WHEN COMPARED TO INTRAVENOUS FORMULATIONS.FIXED-DOSE COMBINATION ADMINISTERED UNDER SKIN IN JUST MINUTES, COMPARED TO HOURS WITH INTRAVENOUS ADMINISTRATION, SIGNIFICANTLY REDUCING TIME SPENT RECEIVING TREATMENT.

5th Generation Of Roche’s Founder’s Family Runs For Board Of Directors Seat

Dec 9 (Reuters) - Roche Holding AG <ROG.S>::CHANGES IN THE BOARD OF DIRECTORS AND THE CORPORATE EXECUTIVE COMMITTEE OF ROCHE.CHANGES IN THE BOARD OF DIRECTORS AND THE CORPORATE EXECUTIVE COMMITTEE OF ROCHE.AS ALREADY ANNOUNCED IN JULY 2018, DR ANDREAS OERI (70) WILL RETIRE FROM BOARD OF DIRECTORS AFTER 25 YEARS IN OFFICE WITH ANNUAL GENERAL MEETING IN 2020.DR JÖRG DUSCHMALÉ (35), REPRESENTING FIFTH GENERATION OF COMPANY'S FOUNDER'S DESCENDANTS, WILL STAND FOR ELECTION AS HIS SUCCESSOR.

FDA Authorizes Roche Molecular Systems' cobas vivoDx MRSA Diagnostic Test

Dec 5 (Reuters) - U.S. Food and Drug Administration::U.S. FDA - AUTHORIZED MARKETING OF NEW DIAGNOSTIC TEST TO DETECT METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS BACTERIAL COLONIZATION.FDA SAYS GRANTED MARKETING AUTHORIZATION OF NEW NEW DIAGNOSTIC TEST, CALLED COBAS VIVODX MRSA TEST, TO ROCHE MOLECULAR SYSTEMS INC..

FDA Approves Genentech's Tecentriq Plus Chemotherapy (Abraxane And Carboplatin) For Initial Treatment Of Metastatic Non-Squamous Non-Small Cell Lung Cancer

Dec 3 (Reuters) - Roche Holding AG <ROG.S>::FDA APPROVES GENENTECH’S TECENTRIQ PLUS CHEMOTHERAPY (ABRAXANE AND CARBOPLATIN) FOR THE INITIAL TREATMENT OF METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER.GENENTECH - APPROVAL BASED ON PHASE III IMPOWER130 STUDY.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up